- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05862077
Long-term Exercise Effect of EX1 Exercise Program
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Suwon, Korea, Republic of, 16419
- Sungkyunkwan University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Healthy adults aged 19 to less than 65 years without a history of central nervous system disease
Exclusion Criteria:
- Those who have difficulty walking independently due to problems such as visual field defects or fractures
- Those who have difficulty participating in exercise programs due to adult diseases such as uncontrolled hypertension and diabetes
- Those who are at risk of falling while walking due to severe dizziness
- Those who are less than 140 cm or more than 185 cm in height that is not suitable size for the wearing of the walking assistance robot
- Those who are overweight based on body mass index (BMI) 35 or higher
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Sham Comparator: Overground walking exercise without EX1
Exercise consists of 30 minutes of overground walking.
|
Overground walking without EX1
|
|
Experimental: Exercise program 1 with EX1
Exercise program 1 consists of 30 minutes of overground walking.
|
EX1 is a hip-type assist device developed by Samsung Electronics.
Exercise program 1 for fast walking by applying resistance and assist mode of EX1
|
|
Experimental: Exercise program 2 with EX1
Exercise program 2 consists of 30 minutes of overground walking.
|
EX1 is a hip-type assist device developed by Samsung Electronics.
Exercise program 2 for normal walking by applying resistance and assist mode of EX1
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change on gait function (muscle activation)
Time Frame: Session 0 (initial visit); after session 18 (at approximately 6 weeks)
|
All subjects perform overground walking to assess the change of muscle activation after the interventions using a surface EMG (6 channels).
|
Session 0 (initial visit); after session 18 (at approximately 6 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in heart rate
Time Frame: Every session (total 18 sessions/ 30 minutes)
|
All subjects are measured for heart rate during the intervention.
|
Every session (total 18 sessions/ 30 minutes)
|
|
Reduction in stress level
Time Frame: Session 0 (initial visit); after session 18 (at approximately 6 weeks)
|
We evaluate the subject's usual stress level through a questionnaire. The Perceived Stress Scale (PSS-10) is a 10-item questionnaire originally developed by Cohen et al. (1983) widely used to assess stress levels in young people and adults. The questions ask about feelings and thoughts during the last month. In each case, respondents are asked how often they felt a certain way on a five-point scale from 'never' to 'very often'. Answers are then scored as follow: Never = 0; Almost never = 1; Sometimes = 2; Fairly often = 3; Very often = 4. The PSS score is then obtained by summing across all items. Higher scores indicate higher levels of perceived stress. |
Session 0 (initial visit); after session 18 (at approximately 6 weeks)
|
|
Reduction in body fat percentage
Time Frame: Session 0 (initial visit); after session 18 (at approximately 6 weeks)
|
All subjects are measured for body fat before and after the intervention.
|
Session 0 (initial visit); after session 18 (at approximately 6 weeks)
|
|
User Satisfaction Questionnaire
Time Frame: After session 18 (at approximately 6 weeks)
|
We evaluate the satisfaction questionnaire for EX1 use and exercise program.
|
After session 18 (at approximately 6 weeks)
|
|
Change on gait function (kinematic)
Time Frame: Session 0 (initial visit); after session 18 (at approximately 6 weeks)
|
All subjects perform overground walking to assess the change of kinematic using a motion analysis.
|
Session 0 (initial visit); after session 18 (at approximately 6 weeks)
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 2023-03-005
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.